Reviva Pharmaceuticals Reports $6.4 Million Net Loss in Q1 2025, Seeks Additional Funding

Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $6.4 million for the first quarter of 2025, a decrease from the $7.4 million loss recorded in the same period of 2024. The company's total operating expenses for the quarter were $6.5 million, down from $7.9 million year-over-year, primarily due to reduced research and development costs, which fell to $4.1 million from $5.8 million. General and administrative expenses increased slightly to $2.4 million from $2.1 million. The net loss per share improved to $(0.13) from $(0.25) as the weighted average shares outstanding rose to 48.6 million from 29.9 million.

As of March 31, 2025, Reviva's total assets decreased to $7.1 million from $15.5 million at the end of 2024, largely due to a significant reduction in cash and cash equivalents, which fell to $5.3 million from $13.5 million. Current liabilities also decreased to $11.5 million from $14.6 million, reflecting a reduction in accounts payable and accrued clinical expenses. The company's accumulated deficit increased to $170.7 million from $164.3 million, indicating ongoing financial challenges.

In terms of strategic developments, Reviva's operational focus remains on advancing its clinical trials and product candidates. The company has not reported any significant acquisitions or new product launches during this quarter. However, it has continued to engage in warrant exercises, raising $241,125 through the exercise of warrants, which contributed to its financing activities. The company also recorded stock-based compensation expenses of approximately $919,119, reflecting its ongoing commitment to incentivizing its workforce.

Reviva's operational metrics indicate a need for further funding to sustain its activities. The company has acknowledged that its current cash reserves are insufficient to meet its operational needs beyond the second quarter of 2025. Management has indicated that it will seek additional financing through public or private equity or debt offerings, as well as potential collaborations. The company faces substantial doubt regarding its ability to continue as a going concern within the next year unless it secures additional funding.

Looking ahead, Reviva Pharmaceuticals anticipates continued operating losses as it invests in the research and development of its product candidates. The company expects its expenses to rise in line with its clinical development efforts, and it will need to generate significant revenues to achieve profitability. The management's outlook remains cautious, emphasizing the necessity of securing additional capital to support its ongoing operations and development initiatives.